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Introduction
HIV-specific CD8 + T cell responses play a key role in controlling HIV infection. 1, 2 However, these cells demonstrate an increased sensitivity to CD95/Fas-induced apoptosis and can be killed by HIV-infected cells. 3 This sensitivity to CD95/Fas-induced apoptosis was found highest in effector memory CD45RA -CD62L -and CD45RA + CD62L -HIV-specific CD8 + T cells. 3 This increased apoptosis of HIV-specific CD8 + T cells may be responsible for the skewed memory phenotype of these cells and may impair their function as serial killers. 3, 4 Inhibiting therefore the apoptosis of HIV-specific CD8 + T cells may prove important as a strategy to augment their anti-HIV activity. IL-15 is a pluripotent cytokine that can enhance the generation and survival of murine memory CD8 + T cells both in vitro 5, 6 and in vivo. 5, [7] [8] [9] [10] [11] [12] [13] IL-15 also modulates the effector function of CD8 + T cells as it can increase mRNA expression of perforin, Granzyme A and B and IFN in murine splenocytes 14 and human PBMC. 15 IL-15 can also enhance activation and proliferation of PBMC from HIV-infected individuals, [16] [17] [18] the activity of natural killer cells 17, 19 and the in vitro expansion of cytotoxic CD8 + T cells from HIV-infected individuals. 20 Finally, IL-15 has been shown to inhibit in vitro T cell apoptosis 12, 18, [21] [22] [23] and in vivo anti-Fas induced apoptosis. 22 These properties of IL-15 led us to investigate the effect of IL-15 on the apoptosis and effector function of HIV-specific CD8 + T cells.
We report here that IL-15 greatly reduces spontaneous and CD95/Fas-induced apoptosis of HIV-specific CD8 + T cells. This apoptosis was inhibited in both CD45RA 
Methods
Patients
24 HIV-infected individuals were included in this study that were HIV-positive for at least 1 year (range 3-22 years), the median CD4 count was 205 cells/µl (range18-851), the median viral load was 1466 RNA copies/ml blood (range 36-340000), 21 were asymptomatic and 19 patients were on anti-viral treatment. Peripheral blood was collected following Drexel University Institutional Review Board approval and obtaining informed consent.
Flow cytometry
PBMC were isolated from blood of HIV-infected individuals by Ficoll-Hypaque density centrifugation (Amersham Pharmacia Biotech, Sweden). HIV-specific CD8 + T cells were identified using tetramers of HLA class I A*0201-2-microglobulin loaded with Gag p17 77-85 (SLYNTVATL) peptide and Pol 476-484 (ILKEPVHGV) peptide and tetramers of HLA class I A3-2-microglobulin loaded with Nef 71-80 (QVPLRPMTYK) as previously described. 24 The following antibody combinations were used; Activation studies: anti-CD69-FITC/anti-CD8-PECy5 with Gag-and Pol-specific tetramer-APC; Apoptosis measurement: Annexin V-FITC (kind gift from Dr. J. Tait, U. of Washington, Seattle, WA)/anti-CD8-PE-Cy5 with Gag-and Polspecific tetramer-APC, Annexin V-FITC/anti-CD62L-PE/anti-CD45RA-PE-CY5/ with Gag-and Pol-specific tetramer-APC; Long-time survival studies: Annexin V-FITC/A3-Nef-specific tetramer-PE/anti-CD8-PE-CY5 and Annexin V-FITC/anti-CD8-PE-CY5 with Gag-and Polspecific tetramer-APC (eBioscience, San Diego, CA 
Activation studies
PBMC were cultured in RPMI 1640 supplemented with 10% heat-inactivated FBS, 2 mM LGlutamine, 100 U/ml Penicillin and 100 µg/ml Streptomycin-sulfate (Cellgro) at 37 °C in a 5% CO 2 incubator at 1x10 6 cells/ml/well in 24-well plates. For anti-CD3-induced activation, PBMC were cultured in plates coated with 0.01 µg/ml monoclonal anti-CD3 antibody (OKT3) 25 in the presence or absence of 5 ng/ml IL-15 (R&D system, Minneapolis, MN) for 2h and then transferred to uncoated plates for additional 12 h to allow the surface reappearance of the TCR/CD3 complex and permit tetramer staining. For antigen-specific stimulation, PBMCs were incubated with 1 µg/ml HIV-specific tetramer in the presence or absence of 5 ng/ml IL-15 for 3h. 
Cytotoxicity assay
C1R-A2 (HmyC1R-
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Results
IL-15 inhibits spontaneous and CD95/Fas-induced apoptosis of HIV-specific CD8 + T cells
We have previously shown that HIV-specific CD8 + T cells are highly susceptible to CD95/Fas-mediated apoptosis and can be killed by HIV-infected cells. 3 We have proposed that this apoptosis may be responsible for the skewed phenotype that we and others have observed for these cells. Figure 2C ).
IL-15 enhances long-term survival of CD8 + T cells and HIV-specific CD8 + T cells
We then examined whether IL-15 can increase the in vitro survival of HIV-specific CD8 Figure 3A , B).
The same significant reduction in apoptosis was seen, when instead of percentage of apoptosis the absolute number of dead cells (Annexin V + ) were calculated ( Figure 3C ). As we show in this study, IL-15 not only enhances the survival of HIV-specific CD8 + T cells but also their activation and most importantly their effector functions such as cytotoxicity.
These observations are in agreement with previous studies that have shown that IL-15 augments the proliferation of peptide-stimulated lymphocytes from SIV-infected rhesus monkeys 20 and recall antigen-and HIV-specific antigen-stimulated PBMC from HIV-infected individuals. 16, 17 However, in contrast to these previous studies that focused on proliferation, our study directly examined effector function of HIV-specific CD8 + T cells. 15 this is unlikely the mechanism behind the increased cytotoxicity we observe in our 6h assay as IL-15 enhances granzyme B and perforin only after 48h with no effect even at 12h. 15 We also do not believe that the apoptosis decreasing effect of IL-15 plays a major role in The P values were calculated using Student's t-Test for paired samples. 
